Objective: To compare the mean hospital discharge times and perioperative outcomes for radiofrequency volumetric thermal ablation (RFVTA) of fibroids and laparoscopic myomectomy (LM). Methods: The present postmarket. randomized. prospective. single-center. longitudinal. comparative study. conducted in Tiibingen. Germany. evaluated the outcomes of RFVTA and the current standard of care (LM) for symptomatic uterine fibroids in women who desired uterine conservation. The surgeons were blinded to the treatment until all fibroids 
Introduction
Uterine fibroids are the most common pelvic neoplasms in women; they severely impact the quality of life and are the leading indication for a hysterectomy [1.2] . Hysterectomy is the definitive treatment for myomas; however. many patients seek alternative uterine-sparing therapy and desire to conserve their fertility.
Myomectomy is a much-reported surgical option for women with symptomatic fibroids and. until recently. the abdominal approach has been the approach of choice for most surgeons. Over time. patients have requested less invasive procedures and minimally invasive. laparoscopic options are becoming more popular among patients and their gynecologists [3] . With an extremely skilled laparoscopic surgeon. the advantages oflaparoscopic myomectomy (LM) over abdominal myomectomy can include reduced blood loss. less postoperative pain.
shorter hospital stay. and more rapid recovery [4] . However. the technical challenges of multilayer laparoscopic suturing require skill and experience. Case reports of uterine rupture occurring in the second or third trimester of pregnancy following LM have inspired recommendations against the laparoscopic approach in patients with myomas of more than 5 cm in diameter. mUltiple myomas. or deep intramural myomas [5.6] .
Laparoscopic radiofrequency volumetric thermal ablation (RFVTA) provides a safe and effective outpatient treatment option for women with symptomatic uterine fibroids (including those larger than 5 cm) and for women who desire uterine conservation [7] [8] [9] . The present randomized study compared the outcomes ofRFVTA with those ofLM. the standard of care.
Materials and methods
The primary objective of the present study was to compare the mean time to discharge from the hospital following laparoscopic treatment of fibroids by myomectomy or RFVTA. The secondary objective was to compare perioperative outcomes. A 5-year follow-up is planned to study long-term outcomes, such as pregnancy, symptom improvement, recurrence or regrowth of myomas, and reintervention rates.
The study was a postmarket, randomized, prospective, single-center, longitudinal, comparative study to evaluate the outcomes of RFVfA and the current standard of care (LM) for symptomatic uterine fibroids in women who desire uterine conservation. After approval of the study by the Clinical Ethics Committee at Tlibingen University Hospital, potential participants were enrolled between November 1, 2012, and June 30, 2013 from referral centers within Germany. Inclusion and exclusion criteria defined eligibility (Box 1). After being informed of the purpose ofthe study, the required testing, procedures, and assessments, the expected duration, and the potential risks and benefits of study participation, 50 enrollees gave written informed consent and were treated at Tlibingen University Hospital. All participants were Have taken any depot GnRH agonist within 3 months prior to the screening procedures 6 Have an implanted intrauterine or fallopian tube device for contraception that cannot or will not be removed at least 10 days prior to treatment
7
Have chronic pelvic pain not due to uterine fibroids 8
Have known or suspected endometriosis or adenomyosis
9
Have active or history of pelvic inflammatory disease 10 Have a history of, or evidence of, gynecologic malignancy or pre-malignancy within the past 5 years 11
Have had pelvic radiation 12
Have a non-uterine pelvic mass over 3 cm 13
Have a cervical myoma 14 Have 1 or more completely intracavitary submucous fibroids (type 0) or only type 0/1 submucous fibroids that are better treated via hysteroscopic methods 15 In the medical judgment of the investigator should not participate in the study 16 Are not willing to be randomized to treatment Abbreviation: GnRH , gonadotropin-releasing hormone.
women who desired uterine preservation and who were willing to be randomized 1:1 to RFVfA or LM (Fig. 1) .
Prior to randomization, all patients underwent contact laparoscopic ultrasound (LUS) mapping with an Aloka SSD-4000 ultrasound system and a standard Aloka LUS transducer (UST-5526L-7.5; Hitachi Aloka Medical, Wallingford, CT, USA) for imaging and classification of the fibroids according to their location and size (Fig. 2 ) . Laparoscopic ultrasound is a standard step before fibroid treatment by RFVfA but not before LM. The incorporation of LUS before randomization meant that the surgeons had equal access to valuable imaging information regardless of the procedure performed, and were able to plan the treatment accordingly.
Once a patient's fibroids were mapped, classified, and recorded on the treatment case report form, an envelope was drawn that contained the patient's treatment assignment. An independent third-party statistician (Innovative Analytics, Kalamazoo, MI, USA) performed a computer generation of the randomization assignments in blocks of 6 or 4; the patient and the surgeon were blinded to the treatment assignment.
Patients who were randomized to LM underwent the standard surgical procedure in the lithotomy position with 2 additional 5-mm ports and a uterine manipulator placed according to the routine practice ofthe surgeon investigators [10J. Vicryl 0 interrupted sutures were used in a single layer. Two-layer suturing was employed only for deep intra murals or intramurals without serosal or endometrial distortion. Approximately 20 mL of epinephrine (dilution 1 :200) was instilled for vasoconstriction. If the 15-mm morcellator was placed suprapubically and not at the ultrasound port site, this counted as an additional incision. Myomectomy was not performed on intramural myomas that were 1.0-1.5 cm in diameter.
Patients who were randomized to RFVfA remained in the dorsal position, had a tenaculum placed on the cervix, and were treated with the Acessa system (Halt Medical, Brentwood, CA, USA), which consists of an electrosurgical radiofrequency generator and a percutaneously inserted, disposable radiofrequency handpiece with a deployable electrode array (described in detail in the literature [7] [8] [9] ). Two 10-mm ports were placed: 1 for the laparoscope and 1 for the LUS probe. Prior to ablation, the patients had a small tissue biopsy taken of the largest 1 or 2 fibroid(s), using a 16-gauge Bard Magnum laparoscopic core biopsy needle (Bard Biopsy Systems, Tempe, Al, USA). The tissue samples were sent to the laboratory for routine pathologic analysis. The tip of the handpiece was then placed in the same tract as the biopsy needle and advanced to the fibroid, and the electrodes were deployed if appropriate based on the fibroid size (Fig. 3) . Fibroid ablation was then carried out and the tract was coagulated during probe withdrawal to provide hemostasis (Fig. 4) .
The 2 surgeons (S.Y.B. and B.K.) each perform more than 100 LM procedures annually. Neither had prior experience with RFVfA. As part of the pre-study training process, they attended the standard Acessa RFVfA course, which consists of didactic instruction, practice in a simulated laboratory environment, and proctoring of the initial cases.
At the conclusion of surgery, the port sites were closed per standard procedure. Standard post-procedure care included routine monitoring of vital signs and monitoring for any signs of complications. Outcomes data were collected on the appropriate case report forms for all participants. Any complications that occurred during and following the procedure were documented.
The procedure time was defined as randomization time to closure time for both groups. In addition, the total time in the operating room, including the time of anesthesia induction, was documented, as was the time in the post-anesthesia care unit/ recovery room (time from intake to discharge). The hospitalization time was defined as the time between induction of anesthesia and discharge from the hospital. The sample size needed for the comparison ofLM and RFVfA with regard to hospitalization time was based on the following assumptions. The null hypothesis was that RFVfA is more than 10% worse than LM with regard to length of hospital stay, and the alternative hypothesis was that this is not the case; this was tested using a I-sided test of noninferiority of RFVf A relative to LM with an ex level of 0.025. The mean ± SO length of hospital stay for patients undergoing myomectomy was assumed to be 15 ± 16 hours [11] . so the null hypothesis would be rejected if the length of stay for patients receiving RFVfA was less than 16.5 hours (alternatively, if the length of stay for patients receiving RFVfA subtracted from 16.5 hours was at least 0). The assumed mean ± SO length of hospital stay for patients receiving RFVfA was based on the results of a study conducted in the USA and assumed to be 7 ± 4 hours (data not reported in the article [7 ] ) . Assuming that the pooled SO of the difference in the length of hospital stay between the 2 procedures is 11.7 hours, which is the square root ofthe mean of the estimated variances of the 2 procedures, and that the difference in the length of stay between procedures is 9.5 (16.5 -7) hours, the sample size required to reject the null hypothesis with a power of 0.80 was 50 (25 patients per group) (East version 5.4; Cytel, Cambridge, MA, USA).
Analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA) . The significance level associated with the P value for the comparison between groups with regard to the length of hospital stay was 0.025. Significance levels of P values associated with exploratory comparisons between groups presented in the paper were set to 0.05.
Results
Of 11 0 patients assessed for eligibility, 51 were randomized to the 2 interventions; the final analysis included 25 patients in the RFVfA group and 25 patients in the LM group (Fig. 1) . Baseline demographics and intraoperative uterine mapping characteristics for each group are presented in Table 1 . The predominant symptom reported by the patients in the RFVfA and LM groups was heavy menstrual bleeding followed by urinary frequency, pelvic discomfort and pain, backache, localized pain, dysmenorrhea, urinary retention, increased abdominal girth, dyspareunia, uterine pain, and sleep disturbance. There were no significant differences based on Fisher exact test between the 2 groups with regard to any of these symptoms, although this could be because of the relatively small number of patients in each group. Two patients in each group reported infertility.
The mean time between the first incision and closure of the port sites was 1.1 ± 0.4 hours (median 1.1 hours, range 0.6-1.9 hours) for the RFVfA group and 1.3 ± 0.6 hours (median 1.2 hours, range 0.4-2.9 hours) for the LM group (P = 0.16, ttest). The mean time between arrival in post-anesthesia recovery and discharge from the hospi- of RFVfA relative to LM with regard to hospital stay was highly significant (P < 0.001, Wilcoxon test). The mean number oftreated (RFVfA) or excised (LM) fibroids per patient was 2.8 ± 2.6 (median 2.0, range Fig. 3 . Ultrasound view of the radiofrequency needle array within the fibroid capsule. Table 2 ). The rate of treated/ excised fibroids, expressed as a percentage of the fibroids imaged by LUS, was 98.6% (71/72) for RFVfA and 80.3% (49/61) for LM ( Table 2) . For each RFVfA procedure, 2 trocars (1 for the ultrasound probe and 1 for the laparoscopic video) were used. In the LM procedures, 4-5 trocars were used. The mean intraoperative blood loss was 16 ± 9 mL (median 20 mL, range 0-30 mL) for the RFVfA procedures and 51 ± 57 mL (median 35 mL, range 10-300 mL) for the LM procedures (P < 0.001, Wilcoxon test) .
In the RFVfA group, 1 patient had an unplanned hospitalization because she developed vertigo; this was the only complication reported in the RFVfA group. Four patients in the RFVfA group were hospitalized as a standard-of-care measure because they underwent adhesiolysis in addition to the ablative treatment. In the LM group, 1 patient had a suprapubic port site hematoma, which was reported as a complication; no other complications were reported in the LM group. All 25 patients in the LM group were hospitalized overnight to monitor for potential postprocedure bleeding, administer narcotic pain medications, and ascertain their ability to walk by themselves and use the toilet. No complications such as damage to bladder, ureter, bowel, or vessels occurred with either procedure, and there were no conversions to laparotomy.
Discussion
Although the use and success of RFVf A of uterine fibroids has been reported in the literature [7] [8] [9] 12 ]' there have been no studies to date comparing RFVfA with the current standard of care, LM. The present study was a randomized clinical trial comparing the perioperative outcomes ofthe 2 procedures-specifically, the number oftrocars used, intraoperative blood loss, number of fibroids treated, complications, and times to discharge. These are important parameters to consider because they indicate the comparative need for treatment resources and may predict the quality of life after fibroid treatment.
Several studies of operative time, intraoperative blood loss, and duration of hospitalization associated with LM have been reported. Bedient et al. [13] retrospectively reviewed the charts of 41 women who had undergone LM; the mean operating time was 1.93 ± 1.07 hours (range 1.13-5.35 hours). Nezhat et al. [14] reported on LM surgical times, intraoperative blood loss, and duration of postoperative hospitalization for 35 women undergoing LM. The mean surgical time was 3.38 hours (range 1.58-5.50 hours), the mean blood loss was 420 mL (range 110-750 mL), and the mean duration of postoperative hospitalization was 1.05 days (range 1-3 days) . The perioperative outcomes in these 2 studies [13, 14] may reflect standard-of-care results for LM.
The finding that the present surgeons were able to access and ablate more fibroids by RFVfA than were excised at LM reflects the comprehensiveness of fibroid RFVfA and the possibility to ablate small, intramural myomas without a myometrial incision. The shorter operative and hospitalization times and the lower intraoperative blood loss associated with RFVfA indicate a lower burden overall to medical institutions, patients, and society.
Surgeons are often concerned over the potential for intra-and postoperative bleeding from myometrial incisions. In the present study, there was a meaningful difference in intraoperative blood loss between the 2 groups. Given the difference in the number oftrocars used (2 for RFVfAand 4-5 for LM) and the need for a morcellatorwith LM, patients treated by LM were approximately twice as likely to experience bleeding (hematoma) at a port site. In addition, the placement of trocars carries an inherent risk of intra-abdominal injury [15] .
Like all single-site studies, the present study has limitations. The racial makeup ofthe participants was homogeneous (100% white); a more heterogeneous population might have resulted in decreased bias.
However, all participants had symptomatic fibroids and their surgeons had extensive experience in LM but no experience with RFVfA prior to training for the study. Another limitation of the study as presented is the lack of long-term data, including pregnancy outcomes. The participants will be followed for 5 years and pregnancy outcomes, symptom improvement, and overall treatment satisfaction will be evaluated on the basis of the participants' responses to validated questionnaires.
In summary, RFVfA provided a safe and shorter operative and postoperative experience for patients with myomas with less intraoperative blood loss, treatment of a greater number of fibroids, no myometrial incisions, and less fatigue compared with LM.
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